International Journal of STD & AIDS > Volume 20, Number 8 > Pp. 580-581

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Falasca, K Articles by Vecchiet, J PubMed PubMed Citation Social Bookmarking                      What's this?

Case reports

Severe HIV-associated hypertriglyceridaemia treated with rosuvastatin plus omega-3 fatty acids

K Falasca MD ^*, C Ucciferri MD ^*, P Mancino MD ^*, E Pizzigallo MD ^*, L Calza MD  and J Vecchiet MD ^* 

^* Infectious Diseases Clinic, Department of Medicine and Aging. ‘G. d'Annunzio’ University, Chieti-Pescara; Infectious Diseases Clinic, Department of Medicine, Aging and Nephrology, University of Bologna, Italy

Correspondence to: Professor J Vecchiet, Department of Medicine and Aging, Infectious Diseases Clinic, School of Medicine, ‘G. d'Annunzio’ University, Via dei Vestini 66100 Chieti, Italy Email: jvecchiet{at}unich.it

Compared with healthy controls, HIV patients already have abnormal lipoprotein concentrations before the initiation of highly active antiretroviral therapy (HAART), which worsen with the therapy. HAART-associated dyslipidaemia features fundamental proatherogenic changes such as increased plasma triglycerides (TGs), increased total cholesterol and low-density lipoprotein cholesterol as well as decreased high-density lipoprotein cholesterol (HDL-C). The current guidelines for managing HIV-associated dyslipidaemia recommend diet and exercise counselling, alteration of HAART regimen or addition of lipid-lowering medications such as statins, fibrates and omega-3 (OM-3) fatty acids. Given that cardiovascular risk significantly increases with elevated lipid levels, selecting a drug to manage dyslipidaemia is particularly important. A case is described of an HIV patient who had severe hypertriglyceridaemia and bad metabolic parameters treated with rosuvastatin and OM-3 fatty acids. So we obtained a more marked reduction of TG levels than has never been described before in the literature, associated with a significant increase in HDL-C levels.

Key Words: HIV • rosuvastatin • omega-3 • hypertriglyceridaemia

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?